Novavax (NVAX) Stock Price, Quote, News & History | Benzinga

Novavax Inc (NVAX) Stock Price, Quote, News & History

NVAXNASDAQ

Trade with Public

Trade with Public

$10.38

0.0350.34%

Last update: Sep 4, 10:09 AM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$10.50

Close

-

Volume / Avg.

1.38M / 4.28M

Day Range

$10.31 - $10.75

52 Wk Range

6.20 - 11.97

Market Cap

$1.71B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

72

Short Interest

28.98%

Days to Cover

14.03

Recent Novavax, Inc. News

Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor

Novavax is rising on investors reaction to an unconfirmed rumor that Matrix-M has a favorable safety profile with self-limiting side effects.

Dylan Berman

What's Going On With Novavax Stock?

Shares of Novavax are trading higher Tuesday. The stock is up over 30% over the trailing month as traders weigh updated autumn vaccine authorizations against the company's broader strategic pivot toward licensing and cost-structure optimization.

Henry Khederian

Novavax Stock Climbs Monday: What's Going On?

Shares of Novavax are trading higher Monday, extending its 30% monthly gains on COVID-19 vaccine approvals and broader biotech strength.

Henry Khederian

Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday. On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Avi Kapoor

QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax

FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.

Benzinga News-desk

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-36.90M

Investing Cash Flow (TTM)

-109.51M

Financing Cash Flow (TTM)

74.71M

Free Cash Flow (TTM)

-43.03M

Capital Expenditure (TTM)

-6.12M

Net Change in Cash (TTM)

-71.70M

Analyst Trends and Forecast

0

0

0

0

May

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.1

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.28B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

4.16

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-14.80%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$1.16

Company Debt

Total Debt

$291.49M

LT Debt

$291.49M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$8.36M

Total Cash

$191.46M

Debt to Equity

-

Issuance of Debt (TTM)

$34.24M

Repayment of Debt (TTM)

-$8.36M

Key Statistics

Open

$10.50

Close

-

Volume / Avg.

1.38M / 4.28M

Day Range

$10.31 - $10.75

52 Wk Range

6.20 - 11.97

Market Cap

$1.71B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

72

Short Interest

28.98%

Days to Cover

14.03

About

Sector

Health Care

Industry

Biotechnology

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish su...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Novavax (NVAX) stock?

A

You can purchase shares of Novavax (NASDAQ:NVAX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Novavax (NVAX) competitors?

A

Other companies in Novavax’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Novavax (NVAX) stock?

A

Novavax has a consensus price target of $12.92.

Q

What is the current price for Novavax (NVAX)?

A

The stock price for Novavax (NASDAQ: NVAX) is $10.375 last updated September 4, 2026 at 10:09 AM EDT.

Q

Does Novavax (NVAX) pay a dividend?

A

There are no upcoming dividends for Novavax.

Q

When is Novavax (NASDAQ:NVAX) reporting earnings?

A

Novavax does not have any upcoming earnings scheduled.

Q

Is Novavax (NVAX) going to split?

A

There is no upcoming split for Novavax.

Q

What sector and industry does Novavax (NVAX) operate in?

A

Novavax is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.